Aspiring to report and analyze all data from “factory to patient,” as the company puts it, Integrichain is merging with a gross-to-net (GTN, although Integrichain prefers “G2N”) specialty firm, daVIZta. That company performs revenue analytics and government-pricing solutions. Its software will be integrated into Integrichain’s iCyte platform, which covers applications from analyzing distributor EDI data to cleansing and compiling patient data for specialty pharmaceuticals.
“Gross-to-net is a key industry obstacle for life sciences, with continuous headlines and regulatory uncertainty placing immense pressure on financial modeling and forecasting,” said Integrichain co-founder and CEO, Kevin Leininger. “We consider G2N a challenge on par with pharma’s patient initiation and adherence challenges, and we are serious about investing in and solving all three.” With the merger, Integrichain now has over 220 data scientists and life sciences experts, including 20 government pricing, commercial contracting specialists.
A year ago, Integrichain had acquired Medical Communication Technologies, another specialty firm in government pricing. In the fall, it announced significant upgrades to its iCyte platform, including enhancements in specialty analytics, patient access management and distributor contract management.